Bicycle Therapeutics logo

BCYC - Bicycle Therapeutics Share Price

$11.2 0.0  0.0%

Last Trade - 17/01/20

Sector
Healthcare
Size
Small Cap
Market Cap £153.3m
Enterprise Value £80.0m
Revenue £7.32m
Position in Universe 3815th / 6416
Bullish
Bearish
Unlock BCYC Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

BCYC Revenue Unlock BCYC Revenue

Net Income

BCYC Net Income Unlock BCYC Revenue

Normalised EPS

BCYC Normalised EPS Unlock BCYC Revenue

PE Ratio Range

BCYC PE Ratio Range Unlock BCYC Revenue

Dividend Yield Range

BCYC Dividend Yield Range Unlock BCYC Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
BCYC EPS Forecasts Unlock BCYC Revenue
Profile Summary

Bicycle Therapeutics PLC, formerly Bicycle Therapeutics Limited, is a clinical-stage biopharmaceutical company. The Company is focused on developing a class of medicines for diseases. The Company’s lead product candidate, BT1718, is a Bicycle Toxin Conjugate (BTC) for oncology indications. BT1718 targets tumors that express Membrane Type 1 matrix metalloprotease (MT1-MMP). The Company is also developing BT5528 and BT8009, which are BTCs targeting Ephrin type-A receptor 2 (EphA2), and Nectin-4, for oncology indications. The Company is also developing cytotoxic T-cell activators, designed to trigger an immune response to tumors.

Directors
Last Annual December 31st, 2018
Last Interim September 30th, 2019
Incorporated October 27, 2017
Public Since May 23, 2019
No. of Shareholders: n/a
No. of Employees: 61
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 17,902,869
Free Float (0.0%)
Eligible for
ISAs
SIPPs
BCYC Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Similar to BCYC
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.